Tripla negatív emlőrák: vizsgálatok itt: Dél-Korea
23 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
- Where
- Daegu, Goyang-si, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06841354 · EU 2024-516834-36-00 - 3. fázisTaking peopleA Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- Where
- Goyang-si, Kyonggi-do, Seoul, Taegu
- Életkor
- 18 év and over
- People
- 2400 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06966700 · EU 2024-520190-12-00 - 1. fázisTaking peopleA Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 102
- Run by
- IntoCell, Inc
See details and how to joinNCT07423117 - 1/2. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Where
- Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 1132 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT03424005 · EU 2023-503629-20-00 - 3. fázisTaking peopleSacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 1530 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06393374 · EU 2023-504962-52-00 - 1. fázisTaking peopleA Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Where
- Gwangmyeong, Seoul
- Életkor
- 19 év and over
- People
- 238 worldwide
- Run by
- NiKang Therapeutics, Inc.
See details and how to joinNCT06586957 - 1/2. fázisTaking peopleRinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 952 worldwide
- Run by
- Genmab
See details and how to joinNCT05579366 - 3. fázisTaking peopleStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
- Where
- Chungcheongnam-do, Daegu, Gyeonggi-do, Seodaemun-gu, Seoul
- Életkor
- 18 év and over
- People
- 1514 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT05633654 · EU 2024-512279-10-00 - 1. fázisTaking peopleA Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Where
- Goyang-si Gyeonggi-do
- Életkor
- 18 év and over
- People
- 575 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06400472 · EU 2024-511238-11-00 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 3. fázisTaking peopleROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
- Where
- Cheonan, Cheongju-si, Goyang-si, Seongnam-si, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 558 worldwide
- Run by
- BioNTech SE
See details and how to joinNCT07173751 · EU 2025-521884-12-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Where
- Busan, Cheongju-si, Jinju, Seoul
- Életkor
- 18 év and over
- People
- 325 worldwide
- Run by
- AbbVie
See details and how to joinNCT06084481 · EU 2023-506227-29-00 - 1/2. fázisTaking peopleA Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07115043 - 1/2. fázisTaking peopleThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Where
- Seoul
- Életkor
- 12 év and over
- People
- 300 worldwide
- Run by
- PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750 - 3. fázisTaking peopleA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Where
- Busan, Daegu, Goyang-si, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 625 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06103864 - 2/3. fázisNot yet taking people in Dél-KoreaA Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Where
- Daegu, Goyang-si, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06926868 · EU 2024-519871-24-00 - 1. fázisTaking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Goyang-si, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - 1. fázisTaking peopleBAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- SillaJen, Inc.
See details and how to joinNCT05768932 - No phaseTaking peopleAn Open-label Prospective Study to Evaluate the Efficacy and Safety of Pegfilgrastim in Triple-Negative Breast Cancer Patients Receiving AC Regimen Following Paclitaxel and Carboplatin as Neoadjuvant Therapy
- Where
- Seoul
- Életkor
- 19 év to 70 év
- People
- 40
- Run by
- Yonsei University
See details and how to joinNCT07525869 - 1/2. fázisTaking peopleA Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Gilead Sciences
See details and how to joinNCT06926920 - 2. fázisTaking peoplePrevention of Sacituzumab Govitecan-related Neutropenia in Patients With Metastatic Triple Negative Breast Cancer
- Where
- Seoul
- Életkor
- 19 év and over
- People
- 40
- Run by
- Yeon Hee Park
See details and how to joinNCT06616987 - 4. fázisTaking peopleViscum Album for TNBC on Adjuvant Pembrolizumab
- Where
- Goyang-si
- Életkor
- 19 év and over
- People
- 40
- Run by
- Ilsan Cha hospital
See details and how to joinNCT06920810 - No phaseTaking peopleLAG3 Expression in Triple Negative Breast Cancer
- Where
- Seoul
- People
- 128
- Run by
- Samsung Medical Center
See details and how to joinNCT06259162